Article in Chemistry & biodiversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
B ChoodamaniDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KAHER-Belagavi), Bengaluru, 560010, Karnataka, India.ORCID http://orcid.org/0000-0002-8920-0580
Karla G Cano HernandezThe Cellular Characterization and Biorepository Core Facility and Border Biomedical Research Center and Department of Biological Sciences, The University of Texas at El Paso, El Paso, 79968, TX, USA.ORCID http://orcid.org/0000-0002-6810-141X
Sujeet KumarDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KAHER-Belagavi), Bengaluru, 560010, Karnataka, India.ORCID http://orcid.org/0000-0002-0833-158X
Ann Maria TonyCenter for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.ORCID http://orcid.org/0000-0001-7833-4439
Austre Y Schiaffino BustamanteThe Cellular Characterization and Biorepository Core Facility and Border Biomedical Research Center and Department of Biological Sciences, The University of Texas at El Paso, El Paso, 79968, TX, USA.ORCID http://orcid.org/0000-0001-6474-1658
Renato J AguileraThe Cellular Characterization and Biorepository Core Facility and Border Biomedical Research Center and Department of Biological Sciences, The University of Texas at El Paso, El Paso, 79968, TX, USA.ORCID http://orcid.org/0000-0003-3765-2793
Dominique ScholsRega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, KU Leuven, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-3256-5850
C Gopi MohanCenter for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.ORCID http://orcid.org/0000-0003-2056-7189
Subhas S KarkiDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KAHER-Belagavi), Bengaluru, 560010, Karnataka, India.ORCID http://orcid.org/0000-0002-5599-3594
Funding
UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Gabriel Andrew Frietze · 2019 to 2026
$35.1M
TOXICOLOGY PROJECTG12RR008124 · NCRR · UNIVERSITY OF TEXAS EL PASO · PI WALSH, ELIZABETH J · 1992 to 2011
$20.8M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
Undergraduate Biomedical Research Training at UTEPT34GM008048 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI PANNELL, KEITH H · 1985 to 2020
$9.2M
Border Biomedical Research Center at UTEPCenter for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, KochiDept. of Chemistry, Indian Institute of Technology, Ropar (Punjab) IndiaNational Institute on Minority Health and Health Disparities (NIMHD) 5 U54MD007592NCRR NIH HHS G12 RR008124NIGMS NIH HHS R25 GM069621NIGMS NIH HHS T34 GM008048NIH-MARC Program T34 GM008048-35NIMHD NIH HHS G12 MD007592NIMHD NIH HHS U54 MD007592NMR Research Center-Indian Institute of Science, Bengaluru (Karnataka) IndiaSophisticated Analytical Instrument Facility (SAIF)-Dharwad, (Karnataka) India
6 · The paper itself
Abstract
In this study, we synthesized 22 compounds in a series with various substitution on imidazo[2,1-b][1,3,4]thiadiazole. The potential cytotoxic activity of these compounds investigated in leukemia cell lines by Differential Nuclear Staining (DNS). Our results identified two compounds, 2-(4-methoxybenzyl)-6-(2-oxo-2H-chromen-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl thiocyanate and 6-(4-chlorophenyl)-2-(4-methoxybenzyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde, exhibited the most cytotoxic effect against murine leukemia cells (L1210), human T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa) with IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole. · full record | OpenQuestion